Guardant Health reported Q1 2026 revenue growth of 48% year over year and raised its full-year 2026 guidance after gains in minimal residual disease and screening. The company posted $301.7 million in Q1 revenue versus $203.5 million a year earlier, with management citing volume increases and reimbursement-driven growth across key oncology tests. Guardant increased its full-year revenue guidance to $1.30 billion–$1.32 billion, driven by a 47% year-over-year rise in oncology test volumes to 86,000. CEO Helmy Eltoukhy said Guardant360 Liquid volumes grew 30%, while Guardant360 Tissue remained a strong growth contributor. The company also noted an upgrade to Guardant360 Tissue to include whole-transcriptome RNA testing, which it expects to expand adoption among current non-users. Guardant’s Reveal minimal residual disease test volumes more than doubled year over year during the quarter. Separately, Guardant said it has submitted data packages to the CMS MolDx program in breast cancer surveillance and other monitoring settings, which it views as potential reimbursement catalysts.